Covicept Therapeutics Initiates a Phase 2 Clinical Study with PJS-539, an Oral Small Molecule for the Treatment of Patients with COVID-19 (SARS-CoV-2)

San Diego, USA, Oct. 6 (Korea Bizwire) – Covicept Therapeutics, an antiviral drug development company, announced today that a double-blind, placebo-controlled Phase 2 trial of PSJ-539 has been initiated and has begun enrolling patients with mild-to-moderate COVID-19. PSJ-539 has the potential to become a best-in-class small molecule for the treatment of COVID-19 patients and also has potential [...]